Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

Mette Ilander, Ulla Olsson‐Strömberg, Heinrich Schlums, +27

Leukemia

Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma

Jani Huuhtanen, Henna H.E. Kasanen, Katriina Peltola, +17

Journal of Clinical Investigation

ImmunologyNk CellsImmunoeditingSingle-cell CharacterizationImmune Cell Therapy +17

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy

Heidi M. Haikala, Johanna M. Anttila, Elsa Marques, +22

Nature Communications

ApoptosisImmunologyCell DeathImmunotherapyCancer Biology +17

Novel TMEM173 Mutation and the Role of Disease Modifying Alleles

Salla Keskitalo, Emma Haapaniemi, Elísabet Einarsdóttir, +16

Frontiers in Immunology

Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival

Oscar Brück, Olli Dufva, Helena Hohtari, +14

Blood Advances

Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation

Jani Huuhtanen, Shady Adnan Awad, Jason Theodoropoulos, +17

Leukemia

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models

Can Hekim, Mette Ilander, Jun Yan, +11

Cancer Immunology Research

Intrafamily and Interfamilial Phenotype Variation and Immature Immunity in Patients With Netherton Syndrome and Finnish<i>SPINK5</i>Founder Mutation

Katariina Hannula‐Jouppi, Satu‐Leena Laasanen, Mette Ilander, +12

JAMA Dermatology

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells

Anna Kreutzman, Mette Ilander, Kimmo Porkka, +2

OncoImmunology

ImmunologyImmune RegulationCd4 T Cell ResponsesImmunotherapeuticsImmunotherapy +16

Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner

Anna Kreutzman, Beatriz Colom-Fernández, Ana Marcos‐Jiménez, +14

Clinical Cancer Research